the effect of rivaroxaban on the prevention of deep vein thrombosis in nephrotic syndrom

evaluation of the effect of rivaroxaban in comparison with warfarin in preventing deep vein thrombosis in patients with nephrotic syndrom

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220422054617N1

Enrollment

Registered

2022-07-10

Start date

2022-07-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic syndrom. Nephrotic syndrome

Interventions

Intervention 1: Control group: prophylaxis with warfarinTen patients are treated with warfarin as a control group and at the beginning of the study and once every three months until the albumin is les

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed nephrotic syndrome Albumin less than 2.5 in a patient with MGN Albumin less than 2 in other cases of nephrotic syndrome The age of the patient is between 18 and 60 years The patient's bleeding risk according to HAS-BLED criteria is low to moderate risk GFR greater than 60

Exclusion criteria

Exclusion criteria: coagulation disorders pregnancy active cancer taking aspirin taking plavix

Design outcomes

Primary

Measure	Time frame
Deep vein thrombosis after taking rivaroxaban. Timepoint: At the beginning of the study and once every three months. Method of measurement: Color Doppler ultrasound of the deep veins of the lower extremities and renal arteries.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Shafiee

Shiraz University of Medical Sciences

Arash.nik0000@gmail.com+98 917 331 1849

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026